Quidelortho Corporation · NASDAQ:QDEL
Quidelortho — 41st Annual J.P. Morgan Healthcare Conference 2023
25 slides from Quidelortho's conference presentation, Jan 9, 2023
Slide 1: QuidelOrtho 41st Annual J.P. Morgan Healthcare Conference
January 9, 2023 QuidelOrtho 41st Annual J.P. Morgan Healthcare Conference Douglas Bryant Joseph Busky President & Chief Financial Officer Chief Executive Officer
Slide 2: Forward-Looking Statements
© 2023. All Rights Reserved. 2 Forward-Looking Statements Forward-Looking Statements: This presentation of QuidelOrtho Corporation (“QuidelOrtho” or the “Company”) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these
Slide 3: Supplemental Combined Financial Measures and Non-GAAP Financial Measures
© 2023. All Rights Reserved. 3 Supplemental Combined Financial Measures and Non-GAAP Financial Measures Supplemental Combined Financial Measures: This presentation contains unaudited supplemental combined financial information (“Supplemental Combined Information”) that gives effect to the Combinatio
Slide 4: Key Messages
© 2023. All Rights Reserved. 4 Key Messages • Strong Business in Large and Growing Markets: We are an in vitro diagnostics leader with growth opportunities in our Point of Care, Molecular Diagnostics, Labs and Transfusion Medicine businesses • Executing on Integration Ahead of Expectations: Integrat
Slide 5: QuidelOrtho: A Broader-Based, Global In Vitro Diagnostics Competitor
© 2023. All Rights Reserved. 5 QuidelOrtho: A Broader-Based, Global In Vitro Diagnostics Competitor customers in more than approximately approximately 130+ 330 Products $2.6B 38.5% Adjusted Countries and across instruments Total Revenue, Ex- EBITDA Margin2 Territories and assays COVID-191 more than
Slide 6: Highly Experienced Management Team
© 2023. All Rights Reserved. 6 Highly Experienced Management Team Proven track record in creating transformational change and accelerating growth Doug Bryant President and Chief Executive Officer Rob Bujarski Michael Iskra Joe Busky Pat Klein Louise Brandy Michelle Hodges Werner Kroll, PhD Chief Ope
Slide 7: QuidelOrtho is Poised to Meet The Challenges of an Evolving Dx Landscape
© 2023. All Rights Reserved. 7 QuidelOrtho is Poised to Meet The Challenges of an Evolving Dx Landscape DECENTRALIZED CENTRALIZED HOME RETAIL AMBULATORY CLINICS & SPECIALTY SETTINGS HOSPITALS REFERENCE LABS OTC Consumer-Oriented Physician Urgent Surgical Micro- Free Sexual Small-Medium Large Donor N
Slide 8: Strategic Priorities
© 2023. All Rights Reserved. 8 Strategic Priorities Integration and Culture Unite the people, processes and products of QuidelOrtho to accelerate innovation, expand commercial reach and improve patient outcomes across the healthcare continuum within a culture of speed, happiness and engagement. Prod
Slide 9: Overall Integration Goal Is to Create a Company of Purpose
© 2023. All Rights Reserved. 9 Overall Integration Goal Is to Create a Company of Purpose That Enriches and Saves Lives With A Culture That Promotes Employees First and Prioritizes Actions That Support Happy, Inspired and Engaged Team Members Future State Ongoing Business Interim State Integration J
Slide 10: Innovating at the Speed of Light
© 2023. All Rights Reserved. 10 Innovating at the Speed of Light New Products Driving Growth Trajectory Near-Term Mid-Term Long-Term Refresh VITROS IA Menu Expansion Including Low-Cost, Low-Volume Platforms Systems & Novel and Specialty Markers: Software; 20-25 New/Refreshed Assays IA Menu Expansion
Slide 11: Savanna: Our Differentiator in Molecular Diagnostics
© 2023. All Rights Reserved. 11 Our Differentiator in Molecular Diagnostics Personalized, Prompt & Precise Savanna • Less than 25 minutes from sample to result without sacrificing quality & performance • Test Select flexible panel sizes & menus for personalized patient & segment testing along with m
Slide 12: Combined QuidelOrtho Portfolio Presents Outsized Market Potential
© 2023. All Rights Reserved. 12 Combined QuidelOrtho Portfolio Presents Outsized Market Potential The strength of our global footprint and combined product bag will enable us to deliver on our commercial strategy and ambitions Revenue creation through Enhanced distribution Strengthened global cross-
Slide 13: Financials
Financials @® QuidelOrtho”
Slide 14: 2022 Financial Highlights
QuidelOrtho – Proprietary & Confidential. | © 2023. All Rights Reserved. 14 2022 Financial Highlights1 3Q 2022 – YTD Results Summary Total Revenue Revenue Growth, Adjusted EBITDA Adjusted EPS Ex-COVID-192 $3.2B $1.3B3 $11.993 +26% y/y1 +8% y/y3 40.8% margin1 +41% y/y1 FY 2022 Supplemental Combined G
Slide 15: Ahead of Cost Synergy Target
QuidelOrtho – Proprietary & Confidential. | © 2023. All Rights Reserved. 15 Ahead of Cost Synergy Target Identified and started executing on more than $50M in cost synergies Realized Synergies (partial year): Duplicative costs: 2023 Board of directors Executives (CEO, CFO, GC, R&D) Senior management
Slide 16: Capital Deployment: Strong Balance Sheet and Cash Generation
QuidelOrtho – Proprietary & Confidential. | © 2023. All Rights Reserved. 16 Capital Deployment: Strong Balance Sheet and Cash Generation Give Us the Flexibility to Allocate Funds Toward Several Capital Deployment Priorities Support menu expansion and development R&D Investment of innovative new inst
Slide 17: Execution of Strategic Priorities Will Position QuidelOrtho for Strong Growth
QuidelOrtho – Proprietary & Confidential. | © 2023. All Rights Reserved. 17 Execution of Strategic Priorities Will Position QuidelOrtho for Strong Revenue and Earnings Growth Assumptions • High end of range driven by strength in 3-Year Outlook (2023-2025) Labs and Savanna • COVID-19 revenue moderate
Slide 18: Closing
Closing @® QuidelOrtho”
Slide 19: Key Messages
QuidelOrtho – Proprietary & Confidential. | © 2023. All Rights Reserved. 19 Key Messages • Strong Business in Large and Growing Markets: We are an in vitro diagnostics leader with growth opportunities in our Point of Care, Molecular Diagnostics, Labs and Transfusion Medicine businesses • Executing o
Slide 20: Appendix
@® QuidelOrtho”
Slide 21: Large and Growing Markets
© 2023. All Rights Reserved. 21 Large and Growing Markets1 Clinical Immunoassay Molecular Transfusion Point-of-Care Chemistry (Central Lab) Diagnostics Medicine Total Addressable $8.1B $9.0B $19.0B $9.3B $2.3B Market1 Steady State 6-8% 3-5% 6-8% 8-10% 2-4% Growth Expected Drivers • Expanded access •
Slide 22: Supplemental Combined Revenue by Business Unit (Year-to-Date)
QuidelOrtho – Proprietary & Confidential. | © 2023. All Rights Reserved. 22 Supplemental Combined Revenue by Business Unit (Year-to-Date)1 Year to date Percent Currency Constant Less: COVID-19 Constant Currency (a) In millions 3Q 2022 3Q 2021 Change Impact revenue impact Currency (a) ex COVID-19 rev
Slide 23: Non-GAAP Reconciliations – Adjusted Net Income
QuidelOrtho – Proprietary & Confidential. | © 2023. All Rights Reserved. 23 Non-GAAP Reconciliations – Adjusted Net Income Year to date In millions, except per share data 3Q 2022 Diluted EPS 3Q 2021 Diluted EPS Net income $ 518.4 $ 9.56 $ 412.9 $ 9.72 Adjustments: Amortization of intangibles 78.6 20
Slide 24: Non-GAAP Reconciliations – Adjusted EBITDA
QuidelOrtho – Proprietary & Confidential. | © 2023. All Rights Reserved. 24 Non-GAAP Reconciliations – Adjusted EBITDA Year to date In millions 3Q 2022 3Q 2021 Net income $ 518.4 $ 412.9 Depreciation and amortization 167.0 37.3 Interest expense, net 41.0 4.7 Provision for income taxes 176.4 112.1 Lo
Slide 25: quidelortho.com
quidelortho.com
QuidelOrtho — 41st Annual J.P. Morgan Healthcare Conference 2023 on 6ix